Nearly 13,000 patients have benefited from IMRIS VISIUS iMRI

2014 procedures expected to increase 31% over 8-year total as intraoperative MRI utilization expands to improve outcomes in growing number of neurosurgical applications

IMRIS Inc. (IMRS) (IM.TO) ("IMRIS" or the "Company") today announced that an internal study of 40 worldwide VISIUS^® Surgical Theatre hospital customers indicates that nearly 13,000 patients have been treated using intraoperative MRI (iMRI) since the first installation in 2005. Four of 27 US hospitals - located in Boston, MA; St. Louis, MO; and Minneapolis and St. Paul, MN - currently using VISIUS iMRI are approaching 1,000 cases performed.

Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test - AmpliVue(R) Group B Strep Assay

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its AmpliVue Group B Strep Assay. AmpliVue is Quidel's non-instrumented molecular diagnostic test that employs a novel amplification technology with an easy-to-use, hand-held device. The AmpliVue Group B Strep Assay combines isothermal Helicase Dependent Amplification (HDA) with Quidel's well-established expertise in lateral flow technology to detect Group B Streptococcus (GBS) from enriched broth cultures of specimens from antepartum women.

Navidea Biopharmaceuticals Submits Supplemental New Drug Application (sNDA) for Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer

- sNDA includes data from successful Phase 3 study in patients with head and neck cancer -

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Lymphoseek^® (technetium 99m tilmanocept) Injection for sentinel lymph node (SLN) detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month. Lymphoseek is currently approved for use in lymphatic mapping procedures that are performed to aid in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma.

BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

BG Medicine, Inc. (BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT(R) Code 82777) at the amount of a crosswalked test (analyte-specific CPT(R) Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013.

"We are very pleased that CMS has finalized the previously announced preliminary determination of the Medicare reimbursement rate for our galectin-3 test," said Dr. Paul R. Sohmer, President and Chief Executive Officer of BG Medicine.